Fecal transplantation from humans with obesity to mice drives a selective microbial signature without impacting behavioral and metabolic health
May 2, 2025 / gut microbiota obesity / fecal microbiota transplantation study / obesity and mental health / microbiome behavioral effects / mouse model metabolomics
Fecal microbiota transplantation from humans with obesity to mice induced minor, specific microbial and metabolite changes—like increased Eubacterium and cecal metabolites—but did not impact weight, glucose metabolism, or anxiety/depression-like behaviors in mice on a low-fat diet.
ASU invention helps people worldwide reach weight goals
May 5, 2025 / resting metabolic rate / personalized weight loss device / Breezing Med obesity tool / metabolic health technology / respiratory quotient analysis
Arizona State University’s Breezing Med device measures resting metabolic rate and respiratory quotient via breath analysis, enabling clinicians to personalize and adapt weight loss plans. Now FDA-cleared and EU-certified, it supports global obesity management in clinical settings.
Wegovy treated a serious form of liver disease in a major clinical trial
April 30, 2025 / Wegovy liver disease trial / MASH semaglutide treatment / GLP-1 liver fibrosis reversal / fatty liver clinical breakthrough / obesity-related liver inflammation
In a major clinical trial, Wegovy (semaglutide) significantly reduced liver inflammation and fibrosis in patients with MASH, a severe form of fatty liver disease. The findings highlight its potential as a pharmacologic treatment beyond obesity and diabetes.
Mayo Clinic Minute: Dual procedure combines liver transplant, bariatric surgery
April 30, 2025 / dual liver transplant bariatric surgery / MASLD obesity treatment / Mayo Clinic liver transplant innovation / gastric sleeve with transplant / liver disease obesity management
Mayo Clinic now performs simultaneous liver transplants and sleeve gastrectomy for patients with obesity and advanced MASLD, improving transplant eligibility and long-term outcomes by addressing both liver disease and weight-related complications.
Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults
May 2, 2024 / body roundness index MASLD / non-obese fatty liver disease / visceral fat liver disease Japan / metabolic liver disease predictors / MASLD risk non-diabetic adults
In a large Japanese cohort, body roundness index (BRI) showed a nonlinear but significant association with MASLD in non-diabetic adults, especially in those with lower BMI, highlighting BRI’s utility in identifying metabolically at-risk individuals beyond traditional obesity measures.
Curcumin shows promise for treating obesity, inflammation, and neurodegenerative diseases
April 30, 2025 / curcumin benefits / obesity treatment / anti-inflammatory effects / neurodegenerative disease support / gut-brain axis therapy
Curcumin, a polyphenol from turmeric, shows anti-inflammatory and metabolic benefits that may aid in managing obesity, metabolic syndrome, and neurodegenerative diseases. It modulates inflammation, enhances fat metabolism, and supports gut-brain axis health through diverse molecular pathways.
GIPR-Ab/GLP-1 peptide–antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
April 29, 2025 / GIPR-GLP1 therapy / obesity treatment research / brain receptor weight loss / peptide-antibody conjugate / metabolic disease mouse model
A dual-action peptide–antibody conjugate that blocks brain GIP receptors and activates GLP-1 receptors drives significant weight loss in obese mice, but requires both CNS GIPR and GLP-1R for full metabolic effect.
Obesity and acylcarnitine derivates interplay with coronary artery disease
May 5, 2025 / acylcarnitines / coronary artery disease / obesity metabolism / fatty acid biomarkers / cardiovascular risk markers
In this study, obese patients with coronary artery disease (CAD) showed significantly lower plasma levels of short-chain acylcarnitines and saturated fatty acids, suggesting a metabolomic link between altered fatty acid metabolism and CAD in obesity.
Cardiometabolic health and ASCVD primary prevention: time to take actions
May 3, 2025 / cardiometabolic health / ASCVD prevention / Life’s Vital 9 / global cardiovascular risk / lifestyle intervention
Cardiometabolic disorders significantly elevate global atherosclerotic cardiovascular disease (ASCVD) risk. A new preventive framework, Life’s Vital 9, emphasizes comprehensive lifestyle and metabolic management—including blood pressure, glucose, cholesterol, sleep, and mental health—to improve global cardiovascular outcomes.
RNA-binding proteins: a novel target for modulating glucose and lipid metabolism
May 2, 2024 / ALKBH5 / glucose metabolism / lipid metabolism / MAFLD treatment / RNA-binding proteins
A recent study identifies ALKBH5, an RNA-binding protein, as a dual regulator of glucose and lipid metabolism through GCGR and EGFR-mTORC1 pathways in the liver. Targeting ALKBH5 may offer novel therapies for type 2 diabetes and MAFLD.
Gut bacteria and metabolites reveal depression-linked patterns in older adults
April 29, 2025 / gut microbiota / depression biomarkers / metabolic syndrome / microbial metabolites / gut-brain axis
This study links altered gut microbiota and microbial metabolites—such as elevated Streptococcus, Acidaminococcus, and valeric acid—with depression in older adults with obesity and metabolic syndrome, highlighting the gut-brain axis as a therapeutic target.
Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows
May 4, 2025 / semaglutide / MASH treatment / liver fibrosis / fatty liver disease / metabolic health
Semaglutide significantly improved liver inflammation, fibrosis, weight loss, and cardiometabolic markers in MASH patients with moderate-to-advanced fibrosis, demonstrating its potential as a multi-system therapeutic for fatty liver disease in obese and diabetic populations.
Landmark Study Finds Semaglutide Effectively Treats Serious Liver Disease
May 2, 2025 / semaglutide / MASH treatment / liver fibrosis / fatty liver disease / GLP-1 agonist
Semaglutide significantly improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH), showing promise as a dual-acting treatment targeting both liver disease and underlying metabolic dysfunctions in a global phase 3 trial.
Walking After Meals: Small Habit, Big Metabolic Gains
April 29, 2025 / post-meal walking / blood sugar control / type 2 diabetes prevention / metabolic health / insulin sensitivity
Walking for 10–15 minutes after meals significantly improves postprandial glucose control, reduces insulin resistance, and supports metabolic health, making it an accessible, non-pharmacologic strategy for preventing type 2 diabetes, obesity, and cardiovascular disease.
High fructose diets impair brain function and appetite control, study shows
April 30, 2025 / fructose metabolism / appetite regulation / neuroinflammation / cognitive decline / processed sugar effects
High fructose intake, especially from processed foods, disrupts brain energy regulation, appetite control, and neurocognitive health, promoting hunger, neuroinflammation, and risk for metabolic and neurodegenerative disorders, particularly during critical developmental periods.
Alarming Rates Of Severe Obesity Increasing In America
May 1, 2025 / severe obesity trends / BMI 60 health risks / obesity epidemic America / metabolic disease burden / obesity healthcare impact
Severe obesity (BMI ≥ 60) has increased 210% in the U.S., posing critical health risks and straining healthcare infrastructure due to mobility challenges, comorbidities, and equipment limitations, highlighting the urgent need for targeted public health interventions.
Metabolic treatment: A potential breakthrough in diabetic heart disease
May 1, 2025 / SGLT2 inhibitors heart failure / ketone metabolism diabetes / diabetic cardiomyopathy treatment / dapagliflozin cardiac function / metabolic therapy heart disease
A UT Health San Antonio study shows that increasing ketone availability with SGLT2 inhibitors like dapagliflozin improves cardiac function in Type 2 diabetes patients with heart failure by enhancing energy efficiency and reducing myocardial oxygen demand.
The effects of an anti-inflammatory diet alone or in combination with acupuncture on mental health, anthropometric indices, and metabolic status in diabetic patients with depression: a randomized, controlled clinical trial
May 2, 2025 / acupuncture type 2 diabetes / anti-inflammatory diet depression / diabetes mental health treatment / HbA1C reduction acupuncture / abdominal obesity diabetes therapy
In T2DM patients with mild-to-moderate depression, combining acupuncture with an anti-inflammatory diet significantly improved mental health, reduced HbA1C and waist circumference, and increased HDL cholesterol more effectively than diet alone or standard care over 8 weeks.
Is Berberine Really “Nature’s Ozempic”? What Science Says
April 30, 2025 / berberine metabolic health / natural ozempic comparison / berberine AMPK activation / semaglutide vs berberine / berberine diabetes weight loss
Berberine shows promise in improving glycemic control and lipid metabolism via AMPK activation, but it lacks the receptor-specific action, clinical rigor, and regulatory oversight of Ozempic (semaglutide), making the “nature’s Ozempic” label scientifically inaccurate.